EL
ELDN
Eledon Pharmaceuticals, Inc.
$3.49
-1.55%
$274.0M
No data for this timeframe.
Vol
Market Cap$274.0M
Cap SizeMicro Cap
Inst. Holders7 funds
Inst. Value$7.2M
Inst. Activity3 buys / 1 sells
Reddit Sentiment50° Neutral
SEC Reports1
Press Releases2
Recent Activity
Feb 28, 2026
SEC
Three major passive institutions — Morgan Stanley, Schwab, and UBS — significantly increased their positions in Eledon P
INST-CLUSTER — Impact 4/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
176,990 shares ($267.3K)
Inst.
WELLS FARGO & COMPANY/MN — ADD
68,906 shares ($104.0K)
Jun 9, 2026
short_volume
Short Volume: ELDN — 74.8% short (0.5M / 0.6M)
Short: 466,435 | Exempt: 8,671 | TRF Vol: 623,842 | Short Ratio: 74.8% | Off-exchange volume (dark p
May 20, 2026
Press
Eledon Pharmaceuticals will present new clinical data from its tegoprubart Phase 2 BESTOW trial and extension study at t
Impact 3/10
Mar 10, 2026
Press
Eledon Pharmaceuticals announced that the FDA granted Orphan Drug designation to its investigational therapy tegoprubart
Impact 6/10
Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$8.20 (Nov 2025)
Current $3.50
Low $5.00
Median $8.00
High $12.00
5 analysts
$5.00
$12.00
Analyst Ratings
4Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 18, 2025 | Guggenheim | MAINTAIN | Buy → Buy |
| Sep 2, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jul 25, 2025 | Craig-Hallum | INITIATE | Buy |
| Nov 20, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jun 4, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.15 ▲ +36.5% | $-0.19 — $-0.09 | -17% YoY | 4 |
| Next Q | $-0.18 ▲ +24.5% | $-0.20 — $-0.16 | 12% YoY | 4 |
| Current FY | $-0.87 ▲ +8.6% | $-0.92 — $-0.77 | -68% YoY | 4 |
| Next FY | $-0.72 ▲ +10.0% | $-0.80 — $-0.68 | 17% YoY | 3 |
Latest Reports
NEUTRAL
Press
3/10
Eledon Pharmaceuticals will present new clinical data from its tegoprubart Phase 2 BESTOW trial and extension study at t
May 20, 2026
NEUTRAL
INST-CLUSTER
4/10
Three major passive institutions — Morgan Stanley, Schwab, and UBS — significantly increased their positions in Eledon P
Feb 28, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $6.1M | — |
| MORGAN STANLEY | $363.2K | TRIM |
| RENAISSANCE TECHNOLOGIES LLC | $267.3K | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $261.4K | DOUBLED |
| WELLS FARGO & COMPANY/MN | $104.0K | ADD |
Reddit Sentiment
50°▲
Neutral
Bearish
Neutral
Bullish
7 institutional holders with $7.2M total value (4,764,042 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, RENAISSANCE. Net buying activity: 3 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 4,039,686 | $6.1M | 84.8% | — |
| 2 | MORGAN STANLEY | 240,545 | $363.2K | 5.0% | TRIM -30.8% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 176,990 | $267.3K | 3.7% | TRIM -49.3% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 173,131 | $261.4K | 3.6% | DOUBLED +491.1% |
| 5 | WELLS FARGO & COMPANY/MN | 68,906 | $104.0K | 1.4% | ADD +41.9% |
| 6 | BANK OF AMERICA CORP /DE/ | 60,098 | $90.7K | 1.3% | ADD +32.9% |
| 7 | FMR LLC | 4,686 | $7.1K | 0.1% | DOUBLED +1812.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 349,200 | 176,990 | -49.3% | $267.3K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 48,552 | 68,906 | +41.9% | $104.0K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 45,229 | 60,098 | +32.9% | $90.7K | 2025-Q4 |
| FMR LLC | DOUBLED | 245 | 4,686 | +1812.7% | $7.1K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 190,673 | 349,200 | +83.1% | $904.4K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 345,629 | 239,159 | -30.8% | $619.4K | 2025-Q3 |
| UBS Group AG | TRIM | 126,266 | 93,453 | -26.0% | $242.0K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 37,156 | 48,552 | +30.7% | $125.7K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 25,367 | 45,229 | +78.3% | $117.1K | 2025-Q3 |
| FMR LLC | DOUBLED | 68 | 245 | +260.3% | $635.00 | 2025-Q3 |
| MORGAN STANLEY | ADD | 221,957 | 345,629 | +55.7% | $936.7K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 122,773 | 190,673 | +55.3% | $516.7K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 29,987 | 177,249 | +491.1% | $480.3K | 2025-Q2 |
| UBS Group AG | DOUBLED | 23,225 | 126,266 | +443.7% | $342.2K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEW | — | 37,156 | — | $100.7K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 7,012 | 25,367 | +261.8% | $68.7K | 2025-Q2 |
| FMR LLC | DOUBLED | 17 | 68 | +300.0% | $184.00 | 2025-Q2 |
| MORGAN STANLEY | ADD | 174,506 | 221,957 | +27.2% | $752.4K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 209,570 | 150,297 | -28.3% | $509.5K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 318,581 | 23,225 | -92.7% | $78.7K | 2025-Q1 |
| UBS Group AG | DOUBLED | 4 | 318,581 | +7964425.0% | $1.3M | 2024-Q4 |
| CITADEL ADVISORS LLC | NEW | — | 209,570 | — | $863.4K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 83,471 | 174,506 | +109.1% | $719.0K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 14,987 | 29,987 | +100.1% | $123.5K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 2,155 | 83,471 | +3773.4% | $207.8K | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 4.0/10.
Historical analyst distribution (last covering-analyst action Nov 2025): 92% buy across 12 analysts — 4 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$8.20 mean target (Nov 2025)
$5.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $3.50 |
| Target Low | $5.00 |
| Target Mean | $8.20 |
| Target Median | $8.00 |
| Target High | $12.00 |
| # Analysts | 5 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.15 | $-0.19 | $-0.09 | -17.3% | +36.5% | 2↑ 0↓ | $0.0B | 0.0% | 4 |
| Next Q 2026-09-30 |
$-0.18 | $-0.20 | $-0.16 | 11.9% | +24.5% | 2↑ 0↓ | $0.0B | 0.0% | 4 |
| Current FY 2026-12-31 |
$-0.87 | $-0.92 | $-0.77 | -67.8% | +8.6% | 2↑ 0↓ | $0.0B | 0.0% | 4 |
| Next FY 2027-12-31 |
$-0.72 | $-0.80 | $-0.68 | 17.1% | +10.0% | 2↑ 0↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.152 | |
| 7d ago | $-0.152 | |
| 30d ago | $-0.240 | +0.087 |
| 60d ago | $-0.240 | +0.087 |
| 90d ago | $-0.215 | +0.063 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 4 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 18, 2025 | Guggenheim | MAINTAIN | Buy | Buy |
| Sep 2, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jul 25, 2025 | Craig-Hallum | INITIATE | — | Buy |
| Nov 20, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 4, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 10, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 7, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 22, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 13, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Oct 24, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Sep 27, 2023 | Noble Capital Markets | INITIATE | — | Outperform |
| Aug 22, 2023 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| May 26, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 1, 2022 | SVB Leerink | MAINTAIN | — | Outperform |
| Nov 24, 2021 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Apr 27, 2021 | SVB Leerink | MAINTAIN | — | Outperform |
| Mar 23, 2021 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Feb 8, 2021 | SVB Leerink | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
8 mentions
0 bullish
0 bearish
8 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 7, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 7, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 23, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 23, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 13, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 13, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 12, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 12, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Potential Type 1 Diabetes Cure
▲ 1
💬 0
⚡ 0.5
Anyone in ELDN? I’m too regarded to know fundamentals but just hoping this can explode like Novo
▲ 1
💬 0
⚡ 0.5
Eledon Pharmaceuticals (ELDN)
▲ 1
💬 0
⚡ 0.3
ELDN showing incredible data
▲ 1
💬 1
⚡ 0.5
$ELDN's cure to your poverty
▲ 1
💬 0
⚡ 0.5
$ELDN's Tegoprubart can CURE YOUR POVERTY
▲ 1
💬 0
⚡ 0.5
Jun 9, 2026
short_volume
Short Volume: ELDN — 74.8% short (0.5M / 0.6M)
Short: 466,435 | Exempt: 8,671 | TRF Vol: 623,842 | Short Ratio: 74.8% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: ELDN — 65.1% short (0.5M / 0.7M)
Short: 486,090 | Exempt: 875 | TRF Vol: 746,443 | Short Ratio: 65.1% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
fda
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at AD
Jun 1, 2026
short_volume
Short Volume: ELDN — 57.7% short (0.3M / 0.5M)
Short: 310,439 | Exempt: 1,147 | TRF Vol: 537,817 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
May 26, 2026
short_volume
Short Volume: ELDN — 66.3% short (0.5M / 0.7M)
Short: 462,069 | Exempt: 0 | TRF Vol: 697,445 | Short Ratio: 66.3% | Off-exchange volume (dark pool + OTC)
May 20, 2026
fda
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
Eledon to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at ATC
May 13, 2026
earnings
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 12, 2026
earnings_calendar
ELDN Q1 2026 Earnings Scheduled — 2026-05-12
May 7, 2026
earnings_calendar
ELDN Q1 2026 Earnings Scheduled — 2026-05-07
May 6, 2026
short_volume
Short Volume: ELDN — 59.3% short (0.4M / 0.7M)
Short: 402,186 | Exempt: 5,288 | TRF Vol: 677,657 | Short Ratio: 59.3% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
short_volume
Short Volume: ELDN — 64.6% short (0.3M / 0.5M)
Short: 349,548 | Exempt: 0 | TRF Vol: 541,069 | Short Ratio: 64.6% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
short_volume
Short Volume: ELDN — 57.1% short (0.5M / 0.8M)
Short: 458,173 | Exempt: 1,270 | TRF Vol: 802,520 | Short Ratio: 57.1% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
short_volume
Short Volume: ELDN — 59.1% short (0.5M / 0.8M)
Short: 468,928 | Exempt: 300 | TRF Vol: 793,055 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
short_volume
Short Volume: ELDN — 68.8% short (0.6M / 0.9M)
Short: 586,304 | Exempt: 1,918 | TRF Vol: 852,112 | Short Ratio: 68.8% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
short_volume
Short Volume: ELDN — 69.3% short (0.8M / 1.1M)
Short: 787,452 | Exempt: 0 | TRF Vol: 1,136,186 | Short Ratio: 69.3% | Off-exchange volume (dark pool + OTC)